These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 26263298)

  • 1. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections.
    Bassetti M; Righi E
    Curr Opin Crit Care; 2015 Oct; 21(5):402-11. PubMed ID: 26263298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
    Karakonstantis S; Kritsotakis EI; Gikas A
    Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.
    Karaiskos I; Giamarellou H
    Expert Opin Pharmacother; 2014 Jul; 15(10):1351-70. PubMed ID: 24766095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of novel antibacterial drugs to combat multiple resistant organisms.
    Bassetti M; Righi E
    Langenbecks Arch Surg; 2015 Feb; 400(2):153-65. PubMed ID: 25667169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options.
    Cerceo E; Deitelzweig SB; Sherman BM; Amin AN
    Microb Drug Resist; 2016 Jul; 22(5):412-31. PubMed ID: 26866778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial resistance and treatment: an unmet clinical safety need.
    Bassetti M; Russo A; Carnelutti A; La Rosa A; Righi E
    Expert Opin Drug Saf; 2018 Jul; 17(7):669-680. PubMed ID: 29897796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-resistant gram-negative infections. Bringing back the old.
    Chan-Tompkins NH
    Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
    Hamouche E; Sarkis DK
    Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens.
    Pollini S; Brunetti J; Sennati S; Rossolini GM; Bracci L; Pini A; Falciani C
    J Pept Sci; 2017 Apr; 23(4):329-333. PubMed ID: 28176481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY.
    Landman D; Bratu S; Kochar S; Panwar M; Trehan M; Doymaz M; Quale J
    J Antimicrob Chemother; 2007 Jul; 60(1):78-82. PubMed ID: 17490999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
    Wright H; Bonomo RA; Paterson DL
    Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
    Mezzatesta ML; Caio C; Gona F; Cormaci R; Salerno I; Zingali T; Denaro C; Gennaro M; Quattrone C; Stefani S
    Int J Antimicrob Agents; 2014 Aug; 44(2):112-6. PubMed ID: 25059444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
    Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
    Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections.
    MacVane SH
    J Intensive Care Med; 2017 Jan; 32(1):25-37. PubMed ID: 26772199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates.
    Landman D; Singh M; El-Imad B; Miller E; Win T; Quale J
    Int J Antimicrob Agents; 2014 Jun; 43(6):527-32. PubMed ID: 24796217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.